Supernus (NASDAQ: SUPN) grows Q2 revenue 32% and lifts 2026 outlook
Rhea-AI Filing Summary
Supernus Pharmaceuticals reported strong second quarter 2026 growth, with total revenues of $219.1 million, a 32% increase from $165.5 million a year earlier. Growth was driven by CNS products including Qelbree, GOCOVRI, ZURZUVAE and ONAPGO, which together generated $175.7 million, up 52% year over year.
Despite higher revenue, Supernus recorded an operating loss of $58.0 million and a net loss of $58.4 million, or $1.01 per share, largely due to a non-cash $54.9 million impairment charge related to APOKYN and higher selling, general and administrative expenses. Adjusted operating earnings were $31.2 million versus $40.9 million in 2025. Cash, cash equivalents and current marketable securities rose to $372.1 million as of June 30, 2026.
Management raised full-year 2026 guidance, targeting total revenues of $860–$890 million and adjusted operating earnings of $150–$180 million. Supernus also highlighted a previously announced all-stock merger of equals with Indivior Pharmaceuticals to create a larger diversified CNS biopharmaceutical company, subject to stockholder and regulatory approvals.
Positive
- Total revenues grew 32% to $219.1 million in Q2 2026 from $165.5 million, with growth products contributing $175.7 million, up 52% year over year.
- The Company raised 2026 guidance, projecting $860–$890 million in total revenues and $150–$180 million in adjusted operating earnings (non-GAAP).
- Liquidity strengthened, with cash, cash equivalents, and current marketable securities increasing to $372.1 million as of June 30, 2026 from $308.7 million at year-end 2025.
Negative
- Supernus swung to a Q2 2026 net loss of $58.4 million, or $1.01 per share, versus net earnings of $22.5 million, reflecting weaker GAAP profitability.
- Results included a substantial $54.9 million non-cash intangible asset impairment charge related to APOKYN, contributing to an operating loss of $58.0 million in the quarter.
Filing Explained
If completed, Supernus holders receive stock under a fixed exchange ratio; approvals remain pending and the merger has not closed.
Supernus reports in this Form 8-K that it has entered a definitive agreement with Indivior for a proposed all-stock merger of equals; the transaction has not been reported as completed.
If completed, Supernus common holders would receive stock under a fixed exchange ratio rather than cash consideration, while the filing leaves the number and ownership proportions of the resulting shares unspecified.
Indivior intends to file an S-4 containing a joint proxy statement/prospectus, followed by stockholder votes; those materials are the stated path for resolving the transaction’s detailed terms and approvals.
The filing states that the exchange ratio will not adjust for changes in either company’s share price before closing, so the market value of the stock consideration can change while the ratio remains fixed.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenues Q2 2026: $219.1 million
Revenues from growth products: $175.7 million
Operating earnings (loss) Q2 2026: ($58.0) million
+5 more
8 metrics
Total revenues Q2 2026
$219.1 million
Three months ended June 30, 2026; 32% increase from $165.5 million in 2025
Revenues from growth products
$175.7 million
Combined revenues of four growth products in Q2 2026; 52% increase year over year
Operating earnings (loss) Q2 2026
($58.0) million
Operating loss for the three months ended June 30, 2026
Intangible asset impairment charge
$54.9 million
Non-cash impairment related to APOKYN recorded in Q2 2026
Net earnings (loss) Q2 2026
($58.4) million
Net loss for the quarter; diluted loss per share of $1.01
Cash and marketable securities
$372.1 million
Cash, cash equivalents, and current marketable securities as of June 30, 2026
2026 total revenue guidance
$860–$890 million
Updated full year 2026 outlook as of early August 2026
Adjusted operating earnings guidance 2026
$150–$180 million
Full year 2026 non-GAAP adjusted operating earnings outlook
Key Terms
merger of equals, non-GAAP financial measures, intangible asset impairment charges, contingent consideration, +1 more
5 terms
merger of equals financial
"combine in an all-stock merger of equals"
A merger of equals is when two companies of similar size and value combine into a single business with shared ownership and leadership, rather than one company buying the other. Investors care because it reshuffles who owns and controls the combined company, aims to cut duplicate costs and strengthen market position, but also brings integration risks that can affect future profits and each company’s stock value.
non-GAAP financial measures financial
"This press release contains financial measures that present financial information which do not comply with United"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
intangible asset impairment charges financial
"primarily due to a non-cash $54.9 million intangible asset impairment charge related to APOKYN"
contingent consideration financial
"change in fair value of contingent consideration, depreciation, and intangible asset impairment charges"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
Adjusted operating earnings financial
"Adjusted operating earnings (non-GAAP)(1) were $31.2 million in the second quarter of 2026"
Adjusted operating earnings are a company’s profit from its regular business activities after removing one-time, unusual or non-core items (like restructuring charges, asset sales, or litigation costs) so you see the underlying performance. Investors use this figure like a trimmed-down view of earnings—similar to judging a car’s fuel efficiency without counting one-off repair bills—to compare companies and assess whether operating results are sustainable.
Earnings Snapshot
Total revenues: $219.1 million · Guidance included
three months ended June 30, 2026
Total revenues
$219.1 million
32% increase from $165.5 million in the same period of 2025
Total revenues from commercial products (non-GAAP)
$201.1 million
27% increase from $158.0 million in the same period of 2025
Net earnings (loss)
($58.4) million
Declined from net earnings of $22.5 million in Q2 2025
Adjusted operating earnings (non-GAAP)
$31.2 million
Down from $40.9 million in the same period of 2025
Guidance
For full year 2026, the company projects total revenues of $860–$890 million, GAAP operating earnings (loss) of $(20)–$(50) million, and adjusted operating earnings (non-GAAP) of $150–$180 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Supernus (SUPN) perform financially in the second quarter of 2026?
Supernus reported Q2 2026 revenues of $219.1 million, a 32% increase from $165.5 million a year earlier. Growth products generated $175.7 million, up 52%, while the company posted a net loss of $58.4 million due mainly to a non-cash impairment.
What are the updated 2026 guidance targets for Supernus (SUPN)?
Supernus now guides for 2026 total revenues of $860–$890 million, up from $840–$870 million. It also expects adjusted operating earnings (non-GAAP) of $150–$180 million, compared with previous guidance of $140–$170 million, reflecting confidence in ongoing growth.
Why did Supernus (SUPN) report a net loss in Q2 2026 despite higher revenue?
The company recorded a net loss of $58.4 million in Q2 2026 primarily because of a $54.9 million non-cash intangible asset impairment related to APOKYN and higher selling, general and administrative expenses, which more than offset the strong revenue increase.
How are Supernus’s key CNS products performing in 2026?
Combined revenues from Qelbree, GOCOVRI, ZURZUVAE and ONAPGO reached $175.7 million in Q2 2026, up 52% year over year. Qelbree net sales were $89.2 million, up 15%, while ONAPGO net sales rose to $13.5 million from $1.6 million.
What is the planned merger between Supernus (SUPN) and Indivior?
Supernus and Indivior have entered into a definitive agreement for an all-stock merger of equals to form a diversified CNS biopharmaceutical company. The transaction is subject to stockholder approvals, regulatory clearances, and other customary closing conditions.
What is Supernus’s liquidity position as of June 30, 2026?
As of June 30, 2026, Supernus held $372.1 million in cash, cash equivalents, and current marketable securities, up from $308.7 million at December 31, 2025, primarily due to cash generated from operations.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) | ||||||||||
Registrant’s telephone number, including area code: (301 ) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Exchange Act
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 3, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals (the "Merger"). Supernus and Indivior will host a joint conference call and webcast presentation today, August 3, 2026, at 8:30 a.m. EDT. A live webcast will be available in the Investor Relations sections of the Supernus and Indivior websites, and a replay will be available following the event. An investor presentation, which will be referenced during the webcast, is also available from the Investor Relations section of both companies’ websites.
The information in Item 2.02 (including Exhibit 99.1) regarding the Company’s financial results for the second quarter ended June 30, 2026 is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.
The information in Item 2.02 (including Exhibit 99.1) regarding the Company's financial results for the second quarter ended June 30, 2026 is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.
No Offer or Solicitation
This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication does not constitute a prospectus or prospectus equivalent document. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information about the Merger and Where to Find It
In connection with the proposed transaction, Indivior intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Indivior and a joint proxy statement of Indivior and Supernus (the “joint proxy statement/prospectus”). Each party also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Indivior’s stockholders and Supernus’ stockholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Indivior and Supernus with the SEC at the SEC’s website at www.sec.gov. Copies of the documents filed by Indivior with the SEC will be available free of charge on Indivior’s website at www.indivior.com or by contacting Indivior’s Investor Relations at InvestorRelations@indivior.com. Copies of the documents filed by Supernus with the SEC will be available free of charge on Supernus’ website at www.supernus.com.
2
Participants in the Solicitation
Supernus and Indivior and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement for its 2026 Annual Meeting, which was filed with the SEC on March 27, 2026. Information about directors and executive officers of Supernus is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. Investors may obtain free copies of these documents from Indivior and Supernus as indicated above.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. From time to time, oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements are intended to provide Supernus’s and Indivior’s respective management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “would,” “could,” “should,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. These statements, including statements regarding the proposed merger of equals of Supernus and Indivior, the expected timing of the closing, and the anticipated benefits and prospects of the combined company, are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the risk that the proposed merger may not be completed in a timely manner or at all; the failure to obtain the required approvals of Supernus' or Indivior’s stockholders; the failure or delay in obtaining required regulatory approvals, or the imposition of conditions in connection therewith; the failure to satisfy the other conditions to closing; the possibility that a competing or superior acquisition proposal is made; the fact that the exchange ratio is fixed and will not be adjusted for changes in the market price of Supernus or Indivior shares; the effect of the announcement, pendency or completion of the transaction on the market price of Supernus and Indivior shares; the effect of the additional indebtedness incurred to fund the Special Dividend on the combined company; the effects of business disruption resulting from the announcement or pendency of the transaction; the diversion of management’s attention and resources from ongoing business operations; the effect of the transaction on the parties’ ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business partners; restrictions during the pendency of the transaction that may limit the parties’ ability to pursue business opportunities or strategic transactions; the risk that the anticipated benefits, synergies and cost savings may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the two businesses; significant transaction costs and/or unknown or inestimable liabilities; the risk that the merger does not qualify for its intended treatment as a tax-free reorganization; the occurrence of any event that could give rise to termination of the merger agreement, including in circumstances requiring payment of a termination fee; the risk of stockholder litigation in connection with the transaction; the impact of macroeconomic and market conditions, including economic downturns, international conflict, trade disputes and tariffs; and the other risks identified in Supernus' and Indivior’s filings with the SEC and in the joint proxy statement/prospectus when it becomes available. There can be no assurance that the proposed merger will in fact be consummated in the manner described or at all. These forward-looking statements speak only as of the date of this communication and neither Supernus nor Indivior undertakes any obligation to update any forward-looking statement, except as required by applicable law. This communication also contains non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA margin and cost synergies, which are not calculated in accordance with GAAP, should be considered in addition to and not as substitutes for the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
3
| Exhibit | Description | ||||
| 99.1 | Press Release dated August 3, 2026 filed as an Exhibit pursuant to Item 2.02 hereof. | ||||
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | ||||
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUPERNUS PHARMACEUTICALS, INC. | ||||||||
| DATED: August 3, 2026 | By: | /s/ Timothy C. Dec | ||||||
| Timothy C. Dec Senior Vice President and Chief Financial Officer | ||||||||
5
Filed by: Supernus Pharmaceuticals, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Subject Company: Supernus Pharmaceuticals, Inc.
Commission File No.: 001-35518
Date: August 3, 2026
Exhibit 99.1
Supernus Announces Second Quarter 2026 Financial Results
•Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year.
•Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® , GOCOVRI®, ZURZUVAE®, and ONAPGO™.
•Regulatory submission to the FDA for second supplier for ONAPGO remains on-track for third quarter 2026, with potential approval by mid-year 2027.
•The Company is raising its full year 2026 financial guidance.
•Announced today agreement to merge with Indivior Pharmaceuticals, Inc. (Indivior) creating a diversified CNS biopharmaceutical company with significant scale.
ROCKVILLE, Md., August 3, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2026 and associated Company developments.
“Our first-half 2026 results reflect the continued strength and sustained momentum of our growth products and continued execution on our commercial strategy,” said Jack Khattar, President and CEO of Supernus. “As we look to the remainder of the year, we remain focused on disciplined execution and prudent capital allocation, and we believe we are well positioned to build on this momentum.”
“We are excited about the future of Supernus, even more so following the recent agreement to merge with Indivior Pharmaceuticals, Inc. The combination of these two businesses will form a well-positioned CNS company with a unique profile of scale, growth, and flexibility to pursue additional business development opportunities.”
Commercial Highlights
•ONAPGO net product sales were $13.5 million in the second quarter of 2026. Since the launch in April 2025, and through the end of July 2026, approximately 2,600 enrollment forms have been submitted by approximately 720 prescribers. The Company remains on-track to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) for a second supplier for ONAPGO in the third quarter of 2026, with potential FDA approval by mid-year 2027.
•Collaboration revenue from ZURZUVAE was $35.4 million in the second quarter of 2026. Collaboration revenue represents 50% of the net revenues for ZURZUVAE recorded by Biogen Inc. Second quarter 2026 U.S sales of ZURZUVAE, as reported by Biogen Inc., increased approximately 53% compared to the same period in 2025. The total number of prescriptions for ZURZUVAE increased by 62% in the second quarter of 2026 compared to the same period last year.
1
•Net sales of Qelbree increased 15% to $89.2 million in the second quarter of 2026, compared to the same period in 2025, driven primarily by volume growth. Total IQVIA prescriptions(6) for Qelbree were 264,545 for the second quarter 2026, representing an increase of 17% compared to the same period last year. Prescription growth in the adult and pediatric populations was 25% and 14%, respectively.
•Net sales of GOCOVRI increased 2% to $37.6 million in the second quarter of 2026, compared to the same period in 2025. Total number of prescriptions grew by 9% in the second quarter of 2026 compared to the same period last year.
Product Pipeline Update
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
•The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures.
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression
•The Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
SPN-443 – Novel stimulant for attention-deficit/hyperactivity disorder (ADHD)
•The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in the second half of 2026.
Financial Highlights
This section includes information on non-GAAP financial measures. See "Non-GAAP Financial Information" section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.
2
Revenues
The following table provides information regarding total revenues (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||||||||||||||
| Net product sales | |||||||||||||||||||||||||||||||||||
| Qelbree | $ | 89.2 | $ | 77.6 | 15% | $ | 167.1 | $ | 142.3 | 17% | |||||||||||||||||||||||||
| GOCOVRI | 37.6 | 36.7 | 2% | 72.8 | 67.4 | 8% | |||||||||||||||||||||||||||||
| ONAPGO | 13.5 | 1.6 | 745% | 21.9 | 1.6 | 1267% | |||||||||||||||||||||||||||||
Trokendi XR® | 8.4 | 11.2 | (25)% | 17.9 | 24.0 | (25)% | |||||||||||||||||||||||||||||
Oxtellar XR® | 8.8 | 11.6 | (25)% | 16.2 | 21.8 | (26)% | |||||||||||||||||||||||||||||
APOKYN® | 6.3 | 12.8 | (51)% | 14.0 | 27.8 | (49)% | |||||||||||||||||||||||||||||
Other(2) | 1.9 | 6.5 | (71)% | 6.6 | 15.1 | (57)% | |||||||||||||||||||||||||||||
Total net product sales | 165.7 | 158.0 | 5% | 316.5 | 300.0 | 5% | |||||||||||||||||||||||||||||
Collaboration revenue (ZURZUVAE) (3) | 35.4 | — | 100% | 63.0 | — | 100% | |||||||||||||||||||||||||||||
Total revenues from commercial products (Non-GAAP) (1) (4) | 201.1 | 158.0 | 27% | 379.5 | 300.0 | 27% | |||||||||||||||||||||||||||||
Royalty, licensing and other revenues(5) | 18.0 | 7.5 | 141% | 47.3 | 15.3 | 209% | |||||||||||||||||||||||||||||
| Total revenues | $ | 219.1 | $ | 165.5 | 32% | $ | 426.8 | $ | 315.3 | 35% | |||||||||||||||||||||||||
Total revenues from commercial products (non-GAAP)(1)(4) represent revenues from our product sales to customers and through our collaboration agreement with Biogen.
Other Financial Highlights
•Operating loss was $58.0 million for the second quarter of 2026, compared to an operating earnings of $12.1 for the same period in 2025. The change was primarily due to a non-cash $54.9 million intangible asset impairment charge related to APOKYN in the second quarter of 2026, an increase in selling, general, and administrative expenses associated with the collaboration agreement with Biogen Inc., partially offset by higher revenues.
•Adjusted operating earnings (non-GAAP)(1) were $31.2 million in the second quarter of 2026, compared to $40.9 million for the same period in 2025.
•Net loss and diluted loss per share were $58.4 million and $1.01 for the second quarter of 2026, respectively, compared to net earnings and diluted earnings per share of $22.5 million and $0.40 for the same period in 2025.
•Cash, cash equivalents, and current marketable securities were approximately $372.1 million as of June 30, 2026, compared to $308.7 million as of December 31, 2025. This increase was primarily due to cash generated from operations.
3
Full Year 2026 Financial Guidance
The Company is raising its full year 2026 financial guidance as set forth below (dollars in millions):
| Current Guidance (as of August 4, 2026) | Previous Guidance (as of February 24, 2026) | |||||||||||||
Total revenues include the following(7): ◦ONAPGO net sales of $55 million - $70 million ◦Trokendi XR and Oxtellar XR net sales of $50 million - $60 million | $860 - $890 | $840 - $870 | ||||||||||||
| Combined R&D and SG&A expenses | $630 - $660 | $620 - $650 | ||||||||||||
| Operating earnings (loss) | $(20) - $(50) | $0 - $30 | ||||||||||||
Adjusted operating earnings (non-GAAP)(1) | $150 - $180 | $140 - $170 | ||||||||||||
Non-GAAP Financial Information
This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. We also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We also present total revenues from commercial products, which is also a non-GAAP measure and is calculated as the combined total of total net product sales (GAAP) and collaboration revenues (GAAP). We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company's revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company's 2026 financial guidance is also being provided on both a GAAP and a non-GAAP basis.
| End Notes | ||||||||||||||
(2) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.
(3) Represents proportionate share of collaboration revenue from Biogen’s sales of ZURZUVAE to customers in the U.S. from July 31, 2025, the closing of the acquisition of Sage Therapeutics, Inc.
(4) Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen.
(5) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property.
(6) IQVIA data restatement July 1, 2025.
(7) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenue.
4
Supernus and Indivior Pharmaceuticals, Inc. to Combine in Merger of Equals
In a press release issued on August 3, 2026, it was announced that the Company and Indivior Pharmaceuticals, Inc. have entered into a definitive agreement to combine in an all-stock merger of equals. For more details regarding the agreement and the other transactions contemplated therein (collectively, the Transaction), please review the Company’s Form 8-K filed on August 3, 2026.
Transaction Conference Call Details
Supernus and Indivior will host a joint conference call to discuss the proposed transaction today, August 3, 2026, at 8:30 a.m. Eastern Time.
A live webcast will be available here or from the Investor Relations section of both companies' website at www.supernus.com/Investors and https://ir.indivior.com. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event. To access the call through a conference line, participants may dial (646) 968-2525 (U.S.) or (888) 596-4144 (toll-free), with the conference ID 3225161.
An investor presentation, which will be referenced during the webcast, is also available from the Investor Relations section of both companies' websites.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
About Indivior Pharmaceuticals, Inc.
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
5
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed merger may not be completed; the possibility that competing offers or acquisition proposals for Supernus or Indivior will be made; the delay or failure of the merger conditions to be satisfied (or waived), including the receipt of required approvals from stockholders of Supernus and Indivior; the failure (or delay) to receive the required regulatory approvals of the proposed merger; the possibility that prior to the completion of the transactions contemplated by the merger agreement, Supernus’s or Indivior’s business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions on Supernus’s and Indivior’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the risk that Supernus may be required to pay a termination fee to Indivior in specified circumstances in which the merger agreement is terminated, and the possibility that the existence of such fee may discourage third parties from proposing an alternative transaction; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the restrictions on the conduct of Supernus’s business during the pendency of the merger under the interim operating covenants contained in the merger agreement, which may limit Supernus’s ability to pursue business opportunities, make acquisitions or dispositions, incur indebtedness, make capital expenditures, or otherwise take actions it would have taken absent the merger agreement, or to respond to competitive pressures or developments in its industry; the diversion of the attention and resources of Supernus’s management and employees from ongoing business operations and opportunities as a result of the substantial time and effort required to complete the merger and to prepare for integration; the fact that the exchange ratio is fixed and will not be adjusted for changes in the market price of Supernus or Indivior common stock prior to the consummation of the merger, which may decrease the value of the consideration received by Supernus stockholders in connection with the merger; the risk that the anticipated benefits, synergies and cost savings of the merger may not be realized, or may not be realized within the expected timeframe; the difficulties, costs and unanticipated liabilities associated with integrating the businesses, operations, systems, product portfolios and personnel of Supernus and Indivior; the risk that the combined company may be unable to retain and motivate key employees during the pendency of the merger and following its consummation; Supernus’s ability to sustain and increase its profitability; Supernus’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus’s corporate strategy; Supernus’s future financial performance and projected expenditures; Supernus’s ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; Supernus’s ability to increase its net revenue from its products, and the products of its subsidiaries; Supernus’s ability to commercialize its products, and the products of its subsidiaries; Supernus’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus’s product research and development activities, including the timing and progress of Supernus’s clinical trials, and projected expenditures; Supernus’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus’s product candidates; Supernus’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; Supernus’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’s product candidates; the accuracy of Supernus’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus’s ability to increase its manufacturing capabilities for its products and product candidates; Supernus’s projected markets and growth in markets; Supernus’s product formulations and patient needs and potential funding sources; Supernus’s staffing needs; changes to laws and regulations applicable to the pharmaceuticals industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in Supernus’s and Indivior’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
6
No Offer or Solicitation
This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information about the Merger and Where to Find It
In connection with the proposed Merger, Indivior intends to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of the Company and Indivior that also constitutes a prospectus of Indivior (the “joint proxy statement/prospectus”). Each of the Company and Indivior may also file other relevant documents with the SEC regarding the proposed Merger. This document is not a substitute for the registration statement, the joint proxy statement/prospectus or any other document that the Company or Indivior may file with the SEC. The definitive joint proxy statement/prospectus (if and when available) will be mailed to stockholders of the Company and Indivior. INVESTORS AND SECURITY HOLDERS OF THE COMPANY AND INDIVIOR ARE URGED TO READ THE REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, INDIVIOR AND THE PROPOSED MERGER. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus (if and when available) and other documents filed with the SEC by the Company and Indivior through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge under the “Investor Relations” section of the Company’s website at https://www.supernus.com, and copies of the documents filed with the SEC by Indivior will be available free of charge on Indivior’s website.
Participants in the Solicitation
The Company, Indivior and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company and Indivior in respect of the proposed Merger. Information regarding the directors and executive officers of the Company, and a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s proxy statement for its most recent annual meeting of stockholders and its other filings with the SEC. Information regarding the directors and executive officers of Indivior is set forth in Indivior’s comparable filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Free copies of these documents (when available) may be obtained as described in the preceding paragraph.
7
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| June 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| (unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 179,953 | $ | 128,448 | |||||||
| Marketable securities | 192,114 | 180,222 | |||||||||
| Accounts receivable, net | 211,656 | 187,802 | |||||||||
| Inventories, net | 83,924 | 82,385 | |||||||||
| Prepaid expenses and other current assets | 55,849 | 65,325 | |||||||||
| Total current assets | 723,496 | 644,182 | |||||||||
| Restricted cash | 1,450 | 1,450 | |||||||||
| Property and equipment, net | 10,197 | 10,531 | |||||||||
| Intangible assets, net | 469,459 | 569,456 | |||||||||
| Goodwill | 119,431 | 124,882 | |||||||||
| Deferred income tax assets, net | 49,061 | 38,351 | |||||||||
| Other assets | 55,015 | 63,796 | |||||||||
| Total assets | $ | 1,428,109 | $ | 1,452,648 | |||||||
| Liabilities and stockholders' equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable and accrued liabilities | $ | 108,458 | $ | 107,800 | |||||||
| Accrued product returns and rebates | 198,844 | 161,097 | |||||||||
| Contingent consideration, current portion | — | 31,052 | |||||||||
| Other current liabilities | 40,076 | 38,222 | |||||||||
| Total current liabilities | 347,378 | 338,171 | |||||||||
| Contingent consideration, long-term | 206 | 206 | |||||||||
| Operating lease liabilities, long-term | 29,427 | 30,365 | |||||||||
| Other liabilities | 19,872 | 22,192 | |||||||||
| Total liabilities | 396,883 | 390,934 | |||||||||
| Stockholders' equity | |||||||||||
Common stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 58 | 57 | |||||||||
| Additional paid-in capital | 574,094 | 543,825 | |||||||||
| Accumulated other comprehensive loss, net of tax | (138) | (44) | |||||||||
| Retained earnings | 457,212 | 517,876 | |||||||||
| Total stockholders' equity | 1,031,226 | 1,061,714 | |||||||||
| Total liabilities and stockholders' equity | $ | 1,428,109 | $ | 1,452,648 | |||||||
8
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Loss
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Net product sales | $ | 165,713 | $ | 157,995 | $ | 316,466 | $ | 299,983 | |||||||||||||||
| Collaboration revenue (ZURZUVAE) | 35,350 | — | 62,993 | — | |||||||||||||||||||
| Royalty, licensing, and other revenues | 17,995 | 7,458 | 47,304 | 15,294 | |||||||||||||||||||
| Total revenues | 219,058 | 165,453 | 426,763 | 315,277 | |||||||||||||||||||
| Costs and expenses | |||||||||||||||||||||||
Cost of revenues(a) | 33,669 | 16,827 | 57,060 | 32,590 | |||||||||||||||||||
| Research and development | 29,463 | 22,115 | 68,901 | 49,042 | |||||||||||||||||||
| Selling, general and administrative | 133,637 | 93,551 | 258,810 | 183,495 | |||||||||||||||||||
| Amortization of intangible assets | 25,333 | 20,819 | 50,977 | 40,605 | |||||||||||||||||||
| Intangible asset impairment charges | 54,919 | — | 54,919 | — | |||||||||||||||||||
| Contingent consideration loss | — | — | 2,391 | 7,660 | |||||||||||||||||||
| Total costs and expenses | 277,021 | 153,312 | 493,058 | 313,392 | |||||||||||||||||||
| Operating earnings (loss) | (57,963) | 12,141 | (66,295) | 1,885 | |||||||||||||||||||
| Other income (expense) | |||||||||||||||||||||||
| Interest and other income, net | 2,630 | 4,528 | 5,012 | 8,953 | |||||||||||||||||||
| Interest expense | (2,315) | — | (2,315) | — | |||||||||||||||||||
| Total other income, net | 315 | 4,528 | 2,697 | 8,953 | |||||||||||||||||||
| Earnings (loss) before income taxes | (57,648) | 16,669 | (63,598) | 10,838 | |||||||||||||||||||
| Income tax expense (benefit) | 723 | (5,830) | (2,934) | 166 | |||||||||||||||||||
| Net earnings (loss) | $ | (58,371) | $ | 22,499 | $ | (60,664) | $ | 10,672 | |||||||||||||||
| Earnings (loss) per share | |||||||||||||||||||||||
| Basic | $ | (1.01) | $ | 0.40 | $ | (1.05) | $ | 0.19 | |||||||||||||||
| Diluted | $ | (1.01) | $ | 0.40 | $ | (1.05) | $ | 0.19 | |||||||||||||||
| Weighted average shares outstanding | |||||||||||||||||||||||
| Basic | 58,070,378 | 56,024,771 | 57,860,131 | 55,945,434 | |||||||||||||||||||
| Diluted | 58,070,378 | 56,643,189 | 57,860,131 | 56,688,754 | |||||||||||||||||||
(a) Excludes amortization of intangible assets.
9
Supernus Pharmaceuticals, Inc.
Reconciliations of GAAP to Non-GAAP Financial Information
(unaudited)
Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales
An itemized reconciliation between total revenues on a GAAP basis and total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||||||
Total revenues (GAAP)(a) | $ | 219.1 | $ | 165.5 | 32% | $ | 426.8 | $ | 315.3 | 35% | |||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
| Trokendi XR net product sales | (8.4) | (11.2) | (25)% | (17.9) | (24.0) | (25)% | |||||||||||||||||||||||||||||
| Oxtellar XR net product sales | (8.8) | (11.6) | (24)% | (16.2) | (21.8) | (26)% | |||||||||||||||||||||||||||||
Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP) | $ | 201.9 | $ | 142.7 | 41% | $ | 392.7 | $ | 269.5 | 46% | |||||||||||||||||||||||||
___________________________________________
(a) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenues.
Reconciliation of GAAP Net Product Sales to Non-GAAP Revenues from Commercial Products
An itemized reconciliation between Net product sales on a GAAP basis and total revenues from commercial products, a non-GAAP measure, is as follows (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||||||
Net product sales (GAAP) | $ | 165.7 | $ | 158.0 | 5% | $ | 316.5 | $ | 300.0 | 6% | |||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
Collaboration revenue (ZURZUVAE) | 35.4 | — | 100% | 63.0 | — | 100% | |||||||||||||||||||||||||||||
Total revenues from commercial products | $ | 201.1 | $ | 158.0 | 27% | $ | 379.5 | $ | 300.0 | 27% | |||||||||||||||||||||||||
Total revenues from commercial products, a non-GAAP measure, represents revenues from our product sales to customers and through our collaboration agreement with Biogen.
10
Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Operating earnings (loss) - As Reported (GAAP) | $ | (58.0) | $ | 12.1 | $ | (66.3) | $ | 1.9 | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Amortization of intangible assets | 25.3 | 20.8 | 51.0 | 40.6 | |||||||||||||||||||
| Intangible asset impairment charges | 54.9 | — | 54.9 | — | |||||||||||||||||||
Share-based compensation | 8.6 | 7.5 | 17.1 | 15.6 | |||||||||||||||||||
| Contingent consideration loss (gain) | — | — | 2.4 | 7.7 | |||||||||||||||||||
| Depreciation | 0.4 | 0.5 | 0.9 | 1.1 | |||||||||||||||||||
| Operating earnings - As Adjusted (non-GAAP) | $ | 31.2 | $ | 40.9 | $ | 60.0 | $ | 66.9 | |||||||||||||||
Non-GAAP adjusted operating earnings adjusts for non-cash items, which include amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, depreciation, and intangible asset impairment charges.
Reconciliation of Full Year 2026 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2026 and projected adjusted operating earnings on a non-GAAP basis for the full year 2026 is as follows (dollars in millions):
| Current Guidance (as of August 4, 2026) | Previous Guidance (as of February 24, 2026) | ||||||||||
| Operating earnings (loss) - GAAP | $(20) - $(50) | $0 - $30 | |||||||||
Adjustments: | |||||||||||
| Amortization of intangible assets | $97 | $105 | |||||||||
| Intangible asset impairment charges | $55 | $— | |||||||||
Share-based compensation | $35 | $35 | |||||||||
Contingent consideration loss | $2 | $2 | |||||||||
| Depreciation | $3 | $3 | |||||||||
| Operating earnings - As Adjusted (non-GAAP) | $150 - $180 | $140 - $170 | |||||||||
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
11